Payment overview · 2025
General Payments
$401.29
19 reported records · 10 companies
Healthcare provider profile · identity verified
Jesse J. Jacquez, P.A.-C.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · COLTON, CA · NPI 1285644294
Verified facts
What the public records show
CMS Open Payments records show Jesse J. Jacquez, P.A.-C. received $401.29 in general payments during 2025 across 19 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 552 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 552 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.68 | 20.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.98 | 18.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.30 | 13.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.15 | 10.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.91 | 8.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.81 | 8.7% | 2 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.14 | 6.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.63 | 5.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.66 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.03 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.29 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $81.68 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $72.98 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.30 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.15 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 552 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
163 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
552 | 121 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
552 | 121 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Jardiance | Empagliflozin | 552 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 504 | 188 |
| Metformin Hcl | Metformin Hcl | 468 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 107 |
| Gabapentin | Gabapentin | 307 | 88 |
| Losartan Potassium | Losartan Potassium | 299 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 84 |
| Meloxicam | Meloxicam | 257 | 101 |
| Lisinopril | Lisinopril | 256 | 86 |
| Omeprazole | Omeprazole | 217 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 66 |
| Ibuprofen | Ibuprofen | 205 | 80 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 200 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 199 | 83 |
| Furosemide | Furosemide | 163 | 57 |
| Kerendia | Finerenone | 163 | 34 |
| Donepezil Hcl | Donepezil Hcl | 148 | 52 |
| Simvastatin | Simvastatin | 147 | 54 |
| Fenofibrate | Fenofibrate | 146 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 47 |
| Glipizide | Glipizide | 137 | 43 |
| Benazepril Hcl | Benazepril Hcl | 135 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 45 |
| Alendronate Sodium | Alendronate Sodium | 126 | 43 |
| Carvedilol | Carvedilol | 116 | 29 |
| Naproxen | Naproxen | 108 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 29 |
| Trulicity | Dulaglutide | 97 | 16 |
| Azithromycin | Azithromycin | 96 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 27 |
| Tramadol Hcl | Tramadol Hcl | 89 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 18 |
| Trazodone Hcl | Trazodone Hcl | 80 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 34 |
| Meclizine Hcl | Meclizine Hcl | 70 | 29 |
| Enalapril Maleate | Enalapril Maleate | 68 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 50 |
| Pentoxifylline | Pentoxifylline | 59 | 14 |
| Glimepiride | Glimepiride | 57 | 18 |
| Sertraline Hcl | Sertraline Hcl | 57 | 21 |
| Famotidine | Famotidine | 55 | 15 |
| Potassium Chloride | Potassium Chloride | 54 | 17 |
| Amoxicillin | Amoxicillin | 53 | 43 |
| Cephalexin | Cephalexin | 53 | 44 |
| Eliquis | Apixaban | 50 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 47 | 14 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 21 |
| Nifedipine Er | Nifedipine | 40 | 12 |
| Atenolol | Atenolol | 39 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 38 | 12 |
| Finasteride | Finasteride | 38 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Loperamide | Loperamide Hcl | 32 | 19 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 31 | 26 |
| Baclofen | Baclofen | 30 | 15 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 18 |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Clotrimazole | Clotrimazole | 28 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Prednisone | Prednisone | 25 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 11 |
| Captopril | Captopril | 22 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | 12 |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 16 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.29 · 19 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, LEVORPHANOL TARTRATE, SHINGRIX, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error